In 2025, India’s pharmaceutical sector is demonstrating remarkable dynamism, driven by a blend of global collaborations and homegrown innovation.
Cipla has launched Afrezza, a rapid-acting inhalable insulin, marking a new addition to diabetes treatment options in India. The product offers a needle-free alternative to injectable mealtime insulin and is aimed at improving ease of use and trea...
Glenmark Pharmaceuticals, USA, has announced the commercial launch of its epinephrine injection USP, 30 mg/30 mL (1 mg/mL) multiple-dose epinephrine vial in the US pharmaceutical market. The product expands Glenmark’s hospital injectables portfol...
A new era is unfolding in India’s pharmaceutical landscape in 2025, where innovation, collaboration, and regulatory rigor are driving transformative growth.
The Indian Pharmaceutical Alliance (IPA) has revealed $15 million expenditure to build a dedicated pharmaceutical quality institute in Ahmedabad.
Cipla partners with Pfizer to exclusively market five established brands in India, strengthening acute therapy presence and expanding patient access through a nationwide distribution network.
Alembic Pharmaceuticals Limited has received final approval from the US Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for travoprost ophthalmic solution USP, 0.004%. The product is indicated for the reductio...
The summit commenced with a welcome address by Rajesh Khubchandani, Co-Founder & Managing Director, Team Marksmen Network, who emphasized, “As we start this journey, we have seen a lot of narratives and stories being told. The way a select few organi
Odisha has declared a policy on drugs and medical equipment to bring investments of 25000 crore by 2030. The policy reflects the desire of the state in turning into a large life-sciences hub in eastern India. It was unveiled during the Odisha...
Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals, has signed an exclusive licensing and distribution agreement with Jiangsu Hansoh Pharmaceutical Group. The agreement is for Aumolertinib, a third-generation...
.jpg)
.jpg)
, CDSCO.jpg)